Einzeltreffer — DigiBib

Background: Cervical cancer is one of the most common cancers in Taiwan. Some patients take Chinese herbal medicine (CHM). However, very few current studies have ascertained the usage and efficacy of CHM in patients with cervical cancer. The aim of this study was to investigate the benefits of complementary CHM among patients with cervical cancer in Taiwan.

Methods: We included the newly diagnosed cervical cancer patients who were registered in the Taiwanese Registry for Catastrophic Illness Patients Database between 2000 and 2010. The end of follow-up period was December 31, 2011. Patients who were less than 20 years old, had missing information for age, withdrew from the National Health Insurance (NHI) program during the follow-up period, or only received other TCM interventions such as acupuncture or tuina massage were excluded from our study. After performing 1:1 frequency matching by age and index date, we enrolled 7521 patients in both CHM and non-CHM user groups. A Cox regression model was used to compare the hazard ratios (HRs) of the risk of mortality. The Kaplan-Meier curve was used to compare the difference in survival time.

Results: According to the Cox hazard ratio model mutually adjusted for CHM use, age, comorbidity, treatment, and chemotherapeutic agents used, we found that CHM users had a lower hazard ratio of mortality risk (adjusted HR = 0.29, 95%CI = 0.27-0.31). The survival probability was higher for patients in the CHM group. Bai-Hua-She-She-Cao ( Herba Oldenlandiae , synonym Herba Hedyotis diffusae) and Jia-Wei-Xiao-Yao-San were the most commonly prescribed single herb and Chinese herbal formula, respectively.

Conclusions: Adjunctive CHM may have positive effects of reducing mortality rate and improving the survival probability for cervical cancer patients. Further evidence-based pharmacological investigations and clinical trials are warranted to confirm the findings in our study.

Titel:	Adjunctive Chinese Herbal Medicine Treatment is Associated With an Improved Survival Rate in Patients With Cervical Cancer in Taiwan: A Matched Cohort Study.
Autor/in / Beteiligte Person:	Wang, C ; Lin, KY ; Wu, MY ; Lin, CL ; Lin, JG ; Chang, CY ; Lin, WC ; Yen, HR
Link:	Full Text Finder (Volltext)
Zeitschrift:	Integrative cancer therapies, Jg. 20 (2021), S. 15347354211061752
Veröffentlichung:	Thousand Oaks, CA : Sage Publications, c2002-, 2021
Medientyp:	academicJournal
ISSN:	1552-695X (electronic)
DOI:	10.1177/15347354211061752
Schlagwort:	Adult Cohort Studies Female Humans Medicine, Chinese Traditional Survival Rate Taiwan epidemiology Young Adult Drugs, Chinese Herbal therapeutic use Uterine Cervical Neoplasms drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Integr Cancer Ther] 2021 Jan-Dec; Vol. 20, pp. 15347354211061752. MeSH Terms: Drugs, Chinese Herbal* / therapeutic use ; Uterine Cervical Neoplasms* / drug therapy ; Adult ; Cohort Studies ; Female ; Humans ; Medicine, Chinese Traditional ; Survival Rate ; Taiwan / epidemiology ; Young Adult References: Lancet Oncol. 2010 Nov;11(11):1018-20. (PMID: 20864403) ; Integr Cancer Ther. 2018 Sep;17(3):665-673. (PMID: 29431027) ; Head Neck. 2019 Sep;41(9):2860-2872. (PMID: 30985039) ; Integr Cancer Ther. 2018 Jun;17(2):531-541. (PMID: 28665160) ; Crit Rev Oncol Hematol. 2000 Sep;35(3):181-200. (PMID: 10960800) ; Psychooncology. 2014 Jun;23(6):672-8. (PMID: 24481859) ; Eur J Oncol Nurs. 2009 Sep;13(4):262-7. (PMID: 19640788) ; J Ethnopharmacol. 2017 Jul 12;206:184-192. (PMID: 28571726) ; Cancer Nurs. 2011 Nov-Dec;34(6):464-9. (PMID: 21372700) ; Biosci Trends. 2010 Dec;4(6):297-307. (PMID: 21248427) ; Evid Based Complement Alternat Med. 2016;2016:9174903. (PMID: 26989427) ; Integr Cancer Ther. 2020 Jan-Dec;19:1534735420943280. (PMID: 32783567) ; J Clin Oncol. 2009 Jun 20;27(18):3052-8. (PMID: 19451437) ; Biosci Trends. 2015 Feb;9(1):16-34. (PMID: 25787906) ; Evid Based Complement Alternat Med. 2018 Feb 12;2018:6517034. (PMID: 29619072) ; Oncol Lett. 2017 Jun;13(6):4748-4754. (PMID: 28588727) ; BMC Womens Health. 2017 Apr 12;17(1):30. (PMID: 28403855) ; J Pharm Biomed Anal. 2018 Feb 5;149:9-15. (PMID: 29100031) ; Carbohydr Polym. 2017 Jul 1;167:90-96. (PMID: 28433181) ; Oncol Lett. 2015 Apr;9(4):1962-1970. (PMID: 25789077) ; Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103. (PMID: 17161167) ; Lancet. 2017 Feb 25;389(10071):847-860. (PMID: 27814965) ; Biomed Pharmacother. 2019 Jan;109:969-984. (PMID: 30551551) ; Med Care. 2005 Feb;43(2):132-40. (PMID: 15655426) ; Br J Cancer. 2012 Mar 27;106(7):1353-60. (PMID: 22353805) ; CA Cancer J Clin. 2016 Jul;66(4):337-50. (PMID: 26891458) ; J Food Drug Anal. 2018 Apr;26(2S):S88-S95. (PMID: 29703390) ; J Clin Oncol. 2000 Apr;18(8):1606-13. (PMID: 10764420) ; Lancet Oncol. 2012 Aug;13(8):790-801. (PMID: 22658655) ; Br J Cancer. 2009 Jul 7;101(1):174-7. (PMID: 19536091) ; Lancet. 1997 Aug 23;350(9077):535-40. (PMID: 9284774) ; Lancet. 2011 Oct 22;378(9801):1461-84. (PMID: 21924486) ; Gynecol Oncol. 2010 May;117(2):281-6. (PMID: 20170944) ; Integr Cancer Ther. 2018 Jun;17(2):411-422. (PMID: 28774207) ; Sci Rep. 2015 Dec 16;5:18111. (PMID: 26669761) ; Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310) ; Chin J Integr Med. 2019 Jun;25(6):425-430. (PMID: 29790063) ; Gynecol Oncol. 2005 Nov;99(2):432-6. (PMID: 16137753) ; J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. (PMID: 30659131) ; Int J Womens Health. 2019 Feb 08;11:135-141. (PMID: 30804687) ; PLoS One. 2016 Apr 11;11(4):e0151502. (PMID: 27064569) ; Front Immunol. 2020 Feb 20;11:62. (PMID: 32153559) ; J Epidemiol. 2017 May;27(5):235-241. (PMID: 28142047) ; J Asian Nat Prod Res. 2013;15(5):550-65. (PMID: 23600735) ; J Clin Oncol. 2004 Aug 1;22(15):3113-9. (PMID: 15284262) ; Nephron. 2018;140(3):175-184. (PMID: 30138926) ; Int J Clin Exp Med. 2015 Mar 15;8(3):4059-65. (PMID: 26064310) ; JAMA Netw Open. 2019 Apr 5;2(4):e192696. (PMID: 31002328) ; J Ethnopharmacol. 2017 Mar 6;199:168-174. (PMID: 28163114) ; Int J Oncol. 2010 Nov;37(5):1331-8. (PMID: 20878081) ; Integr Cancer Ther. 2017 Jun;16(2):156-164. (PMID: 27531548) ; Medicine (Baltimore). 2019 Mar;98(11):e14848. (PMID: 30882680) ; Nat Prod Res. 2020 May;34(10):1345-1351. (PMID: 30449170) ; Drug Des Devel Ther. 2018 Oct 15;12:3459-3469. (PMID: 30410307) ; Breast Cancer Res Treat. 2010 Feb;120(1):111-8. (PMID: 20054647) ; Lancet. 2008 Jun 28;371(9631):2173-82. (PMID: 18586172) ; Oncol Lett. 2016 Jun;11(6):3875-3881. (PMID: 27313710) ; Taiwan J Obstet Gynecol. 2018 Dec;57(6):846-852. (PMID: 30545539) Contributed Indexing: Keywords: Chinese herbal medicine; cervical cancer; integrative medicine; real-world evidence; survival rate; traditional Chinese medicine Substance Nomenclature: 0 (Drugs, Chinese Herbal) Entry Date(s): Date Created: 20211220 Date Completed: 20220425 Latest Revision: 20220425 Update Code: 20240513 PubMed Central ID: PMC8721688

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Adjunctive Chinese Herbal Medicine Treatment is Associated With an Improved Survival Rate in Patients With Cervical Cancer in Taiwan: A Matched Cohort Study.